FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979429674> ?p ?o ?g. }

• W2979429674 abstract "Abstract Abstract 4143 Myeloablative unrelated cord blood transplantation (MAC-UCBT) is an alternative to transplant in children with acute leukemia or myelodisplastic syndrome (MDS) when a donor is not available. Intravenous (iv) busulfan (Bu) combined with therapeutic drug monitoring-guided dosing has been increasingly used and is associated with higher EFS, lower transplant-related mortality (TRM) and toxicity. Even if iv Bu has a more predictable bioavailability comparing with oral Bu, there is still an important variation in Bu pharmacokinetics (PK) between patients that may cause treatment failure and toxicity. In order to analyze the impact of PK parameters of the first iv Bu dose on the different outcomes of MAC-UCBT for acute leukemia and MDS, we analyzed 34 consecutive transplants performed in children between dec/2000 and dec/2011. Patients or parents provided an informed consent. Median age at transplant was 5.9 (0.6–19) years, and 19 (56%) were male. There were 20 AML, 2 ALL and 12 MDS. A total of 10 and 12 patients with acute leukemia were transplanted in first remission (CR1), second remission (CR2)/advanced phase of disease, respectively. Thirty-one patients received a single UCBT. Eight, and twelve patients received a 6/6, or 5/6HLA-matched graft. Median infused nucleated cells and CD34+ cells were 5.5 × 10⋀7/kg and 2.1 × 10⋀5/kg, respectively. Cyclosporin A and steroids were used as graft versus host disease (GvHD) prophylaxis for all patients and 33 patients received ATG. Conditioning regimen consisted of first-dose PK-adapted Bu (targeted steady-state concentration - Css - between 600–900 ng/ml) and Cy 200 mg/kg (n=30), Melphalan 135 mg/m2 (n=2) or Cy 120 mg/kg and etoposide 30 mg/kg (n=2). Median follow-up was 36 months. After iv Bu first dose, median Css was 555 ng/ml, AUC was 188,901 min*ng/ml and clearance was 4.61 ml/min/kg. Cumulative incidence (CI) of neutrophil (>0.5×10⋀9/L) at D+60 and platelet recovery (>50×10⋀9/L) at D+150 were both 87%. Median time to neutrophil and platelet recovery was 20 days and 67 days, respectively. There were six primary or secondary graft failure. CI of acute GVHD grade II-IV at D+180 was 16%. There were two cases of VOD. Five-years CI of transplant-related mortality (TRM) was 12%. CI of relapse at 5 years was 25%. Estimated event-free survival (EFS) at 5 years was 49%. Estimated overall survival (OS) at 5 years was 64%. First dose Css significantly influenced neutrophil recovery (100% vs. 70% for Css < and > 600 ng/ml, respectively - P=0.002), TRM (0% vs. 27% for Css < and > 600 ng/ml, respectively - P=0.02), EFS (73% vs. 18% for Css < and > 600 ng/ml, respectively- P<0.001) and OS (82% vs. 43% for Css < and > 600 ng/ml, respectively - P=0.005). There was no influence of Css on the incidence of platelet recovery, grade 2–4 aGVHD or relapse. In conclusion, first dose iv Bu PK seems to be a significant prognostic factor after UCBT for malignancies in children, influencing neutrophil recovery, TRM, EFS and OS. A direct toxic effect of Bu and/or a synergistic toxic effect with Cy might explain the worst outcome when first dose iv Bu has a Css higher than 600 ng/ml. It will be important to validate these results in a multicentre study and also to compare these results with patients that received a fixed dose of Bu. Finally, our data reinforces the importance of Bu therapeutic drug monitoring-guided dosing in pediatric HSCT patients. Disclosures: No relevant conflicts of interest to declare." @default.
• W2979429674 created "2019-10-18" @default.
• W2979429674 creator A5032787475 @default.
• W2979429674 creator A5035362595 @default.
• W2979429674 creator A5035522302 @default.
• W2979429674 creator A5035824049 @default.
• W2979429674 creator A5057108813 @default.
• W2979429674 creator A5072425736 @default.
• W2979429674 creator A5080379495 @default.
• W2979429674 creator A5082883166 @default.
• W2979429674 creator A5090105248 @default.
• W2979429674 date "2012-11-16" @default.
• W2979429674 modified "2023-10-06" @default.
• W2979429674 title "Association Between Busulfan First-Dose Pharmacokinetics and Outcome in Children Receiving Myeloablative Busulfan-Based Conditioning Before Unrelated Umbilical Cord Blood Transplantation for Malignancies" @default.
• W2979429674 doi "https://doi.org/10.1182/blood.v120.21.4143.4143" @default.
• W2979429674 hasPublicationYear "2012" @default.
• W2979429674 type Work @default.
• W2979429674 sameAs 2979429674 @default.
• W2979429674 citedByCount "0" @default.
• W2979429674 crossrefType "journal-article" @default.
• W2979429674 hasAuthorship W2979429674A5032787475 @default.
• W2979429674 hasAuthorship W2979429674A5035362595 @default.
• W2979429674 hasAuthorship W2979429674A5035522302 @default.
• W2979429674 hasAuthorship W2979429674A5035824049 @default.
• W2979429674 hasAuthorship W2979429674A5057108813 @default.
• W2979429674 hasAuthorship W2979429674A5072425736 @default.
• W2979429674 hasAuthorship W2979429674A5080379495 @default.
• W2979429674 hasAuthorship W2979429674A5082883166 @default.
• W2979429674 hasAuthorship W2979429674A5090105248 @default.
• W2979429674 hasConcept C112705442 @default.
• W2979429674 hasConcept C126322002 @default.
• W2979429674 hasConcept C141071460 @default.
• W2979429674 hasConcept C143998085 @default.
• W2979429674 hasConcept C2776694085 @default.
• W2979429674 hasConcept C2776755627 @default.
• W2979429674 hasConcept C2776863199 @default.
• W2979429674 hasConcept C2777408962 @default.
• W2979429674 hasConcept C2778461978 @default.
• W2979429674 hasConcept C2778496288 @default.
• W2979429674 hasConcept C2779972918 @default.
• W2979429674 hasConcept C2780611847 @default.
• W2979429674 hasConcept C2780895475 @default.
• W2979429674 hasConcept C2911091166 @default.
• W2979429674 hasConcept C29730261 @default.
• W2979429674 hasConcept C71924100 @default.
• W2979429674 hasConcept C90924648 @default.
• W2979429674 hasConceptScore W2979429674C112705442 @default.
• W2979429674 hasConceptScore W2979429674C126322002 @default.
• W2979429674 hasConceptScore W2979429674C141071460 @default.
• W2979429674 hasConceptScore W2979429674C143998085 @default.
• W2979429674 hasConceptScore W2979429674C2776694085 @default.
• W2979429674 hasConceptScore W2979429674C2776755627 @default.
• W2979429674 hasConceptScore W2979429674C2776863199 @default.
• W2979429674 hasConceptScore W2979429674C2777408962 @default.
• W2979429674 hasConceptScore W2979429674C2778461978 @default.
• W2979429674 hasConceptScore W2979429674C2778496288 @default.
• W2979429674 hasConceptScore W2979429674C2779972918 @default.
• W2979429674 hasConceptScore W2979429674C2780611847 @default.
• W2979429674 hasConceptScore W2979429674C2780895475 @default.
• W2979429674 hasConceptScore W2979429674C2911091166 @default.
• W2979429674 hasConceptScore W2979429674C29730261 @default.
• W2979429674 hasConceptScore W2979429674C71924100 @default.
• W2979429674 hasConceptScore W2979429674C90924648 @default.
• W2979429674 hasLocation W29794296741 @default.
• W2979429674 hasOpenAccess W2979429674 @default.
• W2979429674 hasPrimaryLocation W29794296741 @default.
• W2979429674 hasRelatedWork W2138812418 @default.
• W2979429674 hasRelatedWork W2519236218 @default.
• W2979429674 hasRelatedWork W2530189078 @default.
• W2979429674 hasRelatedWork W2556280457 @default.
• W2979429674 hasRelatedWork W2556667196 @default.
• W2979429674 hasRelatedWork W2557949783 @default.
• W2979429674 hasRelatedWork W2560384446 @default.
• W2979429674 hasRelatedWork W2563175190 @default.
• W2979429674 hasRelatedWork W2572562147 @default.
• W2979429674 hasRelatedWork W2587372743 @default.
• W2979429674 hasRelatedWork W2587635904 @default.
• W2979429674 hasRelatedWork W2588528479 @default.
• W2979429674 hasRelatedWork W2752410122 @default.
• W2979429674 hasRelatedWork W2913950684 @default.
• W2979429674 hasRelatedWork W2972799950 @default.
• W2979429674 hasRelatedWork W2979952615 @default.
• W2979429674 hasRelatedWork W2980524036 @default.
• W2979429674 hasRelatedWork W2991679180 @default.
• W2979429674 hasRelatedWork W3031895819 @default.
• W2979429674 hasRelatedWork W3182027595 @default.
• W2979429674 isParatext "false" @default.
• W2979429674 isRetracted "false" @default.
• W2979429674 magId "2979429674" @default.
• W2979429674 workType "article" @default.